Multinational pharmaceutical company Mylan is working with Drug Controller General of India (DCGI) to launch pretomanid, a medicine used to treat drug- resistant tuberculosis (TB), a top official of the US drug major has said. Non-profit drug developer TB Alliance and Mylan NV had in April announced a global collaboration to make the experimental drug pretomanid for cure of pulmonary tuberculosis. "We have submitted the new drug application to the office of DCGI. We are in an advanced stage of discussion and are working with the office of DCGI... Mylan will be in a position to launch the product in India soon after receiving approvals from DCGI," Mylans global president and executive director Rajiv Malik told PTI during his recent visit to India. This drug is important for India because Prime Minister Narendra Modi said India would get rid of tuberculosis by 2025, he added. Also, Modi launched a campaign to eradicate TB from India by 2025, five years ahead of a globally-set deadline. TB Alliance was currently advancing the development of pretomanid in three ongoing late-stage clinical trials, Mylan had said in April.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!